Neonc Technologies (NASDAQ:NTHI) President Amir Heshmatpour Buys 5,000 Shares

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) President Amir Heshmatpour bought 5,000 shares of the stock in a transaction that occurred on Monday, April 6th. The stock was acquired at an average price of $6.32 per share, for a total transaction of $31,600.00. Following the acquisition, the president directly owned 3,017,000 shares in the company, valued at $19,067,440. The trade was a 0.17% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.

Neonc Technologies Stock Performance

NTHI opened at $5.74 on Tuesday. Neonc Technologies Holdings, Inc. has a fifty-two week low of $3.20 and a fifty-two week high of $12.99. The company’s 50-day moving average is $8.87 and its 200 day moving average is $9.22.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Zacks Research upgraded shares of Neonc Technologies to a “hold” rating in a report on Wednesday, January 14th. Weiss Ratings restated a “sell (e+)” rating on shares of Neonc Technologies in a report on Friday, March 27th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Neonc Technologies presently has an average rating of “Reduce”.

Institutional Investors Weigh In On Neonc Technologies

Several institutional investors and hedge funds have recently added to or reduced their stakes in NTHI. Royal Bank of Canada purchased a new stake in Neonc Technologies in the 1st quarter valued at about $247,000. Bank of America Corp DE purchased a new stake in Neonc Technologies in the 2nd quarter valued at about $801,000. Global Retirement Partners LLC purchased a new stake in Neonc Technologies in the 3rd quarter valued at about $434,000. SLT Holdings LLC purchased a new stake in Neonc Technologies in the 3rd quarter valued at about $100,000. Finally, Foundations Investment Advisors LLC purchased a new stake in Neonc Technologies in the 3rd quarter valued at about $100,000.

Neonc Technologies Company Profile

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.